Get the Stockscreener App
5.205
1.70%
-0.09
Eupraxia Pharmaceuticals Inc stock is traded at $5.205, with a volume of 20,622.
It is down -1.70% in the last 24 hours and up +0.29% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$5.295
Open:
$5.4
24h Volume:
20,622
Relative Volume:
1.72
Market Cap:
$187.17M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-6.7597
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
-1.42%
1M Performance:
+0.29%
6M Performance:
+42.60%
1Y Performance:
+94.94%
1-Day Range:
$5.17
$5.40
1-Week Range:
$5.17
$5.46
52-Week Range:
$2.20
$6.1999
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.205 | 190.59M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.06 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.03 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.80 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.25 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Evaluating Eupraxia Pharmaceuticals Inc. with trendline analysis2025 Volatility Report & Free Expert Verified Stock Movement Alerts - Newser
Eupraxia Pharmaceuticals Inc. Consolidation Zone May Signal Accumulation2025 Winners & Losers & Accurate Entry/Exit Alerts - thegnnews.com
Eupraxia: HC Wainwright raises Buy to $12, PT unchanged. - AInvest
Eupraxia Pharmaceuticals Inc. stock outlook for YEARTrade Entry Report & Long-Term Investment Growth Plans - Newser
Is Eupraxia Pharmaceuticals Inc. stock a growth or value playWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - Newser
Can Eupraxia Pharmaceuticals Inc. hit a new high this monthPortfolio Profit Report & Short-Term Trading Opportunity Alerts - Newser
Eupraxia Pharmaceuticals Inc. stock retracement – recovery analysis2025 Dividend Review & Community Consensus Trade Alerts - Newser
How to recover losses in Eupraxia Pharmaceuticals Inc. stockIPO Watch & Technical Entry and Exit Tips - Newser
Heatmap analysis for Eupraxia Pharmaceuticals Inc. and competitorsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - Newser
Eupraxia Pharmaceuticals Inc. stock trend outlook and recovery pathQuarterly Portfolio Report & Technical Confirmation Alerts - Newser
Eupraxia Pharmaceuticals Advances EoE Treatment Trials Amid Financial Challenges - MSN
How to use Fibonacci retracement on Eupraxia Pharmaceuticals Inc.Quarterly Trade Summary & Daily Entry Point Alerts - Newser
Momentum divergence signals in Eupraxia Pharmaceuticals Inc. chart2025 Momentum Check & Expert Curated Trade Ideas - Newser
Is Eupraxia Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Alerts - Newser
Can trapped investors hope for a rebound in Eupraxia Pharmaceuticals Inc.Quarterly Earnings Report & Technical Entry and Exit Alerts - Newser
Is Eupraxia Pharmaceuticals Inc. the Top Chart Pick This WeekPrice Action & AI Driven Price Predictions - 선데이타임즈
What makes Eupraxia Pharmaceuticals Inc. stock price move sharply2025 Year in Review & Fast Moving Stock Watchlists - beatles.ru
Published on: 2025-08-19 05:01:26 - Newser
What data driven models say about Eupraxia Pharmaceuticals Inc.’s futureEarnings Beat & Low Drawdown Investment Strategies - Newser
Eupraxia Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Decliners & Weekly High Potential Stock Alerts - Newser
EPRX FY2025 EPS Forecast Lowered by Cantor Fitzgerald - Defense World
Signal strength of Eupraxia Pharmaceuticals Inc. stock in tech scanners2025 Volatility Report & AI Powered Trade Plan Recommendations - Newser
What’s the recovery path for long term holders of Eupraxia Pharmaceuticals Inc.Market Risk Analysis & Short-Term High Return Ideas - Newser
RSI Suggests Rebound May Be Near in Eupraxia Pharmaceuticals Inc.2025 Key Highlights & Reliable Trade Execution Plans - sundaytimes.kr
Published on: 2025-08-17 03:19:09 - Newser
Analyzing recovery setups for Eupraxia Pharmaceuticals Inc. investorsWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
Using R and stats models for Eupraxia Pharmaceuticals Inc. forecastingJuly 2025 Snapshot & Daily Risk Controlled Trade Plans - Newser
Best data tools to analyze Eupraxia Pharmaceuticals Inc. stockTrade Risk Assessment & Reliable Breakout Stock Forecasts - Newser
Is Eupraxia Pharmaceuticals Inc. forming a reversal patternEarnings Recap Report & Long-Term Safe Investment Plans - Newser
HC Wainwright Issues Pessimistic Forecast for EPRX Earnings - Defense World
Multi asset correlation models including Eupraxia Pharmaceuticals Inc.2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Tools to monitor Eupraxia Pharmaceuticals Inc. recovery probabilityInsider Buying & Weekly Stock Performance Updates - Newser
Institutional scanner results for Eupraxia Pharmaceuticals Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Volume spikes in Eupraxia Pharmaceuticals Inc. stock – what they meanJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
What high frequency data says about Eupraxia Pharmaceuticals Inc.Portfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
Is Eupraxia Pharmaceuticals a buy? - Cantech Letter
Trend Reversal Possible in Eupraxia Pharmaceuticals Inc. Charts IndicateJuly 2025 Sector Moves & Stock Market Timing Techniques - 선데이타임즈
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):